Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab

@article{Maier2020ClinicalIC,
  title={Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab},
  author={Smaranda Maier and Mihaela Adriana Simu and Adina Huțanu and Laura Bărcuţean and Septimiu Voidăzan and Zoltan Bajko and Anca Moţăţăianu and Irina Lata and Rodica Ioana Bălaşa},
  journal={Brain Sciences},
  year={2020},
  volume={10}
}
Natalizumab (NAT) was the first disease modifying therapy used for the treatment of relapsing-remitting multiple sclerosis (MS) that was designed with a specific mechanism of action that targets an important step of the MS immunopathology, directly blocking the T lymphocyte intrusion in the central nervous system. Initially, it was considered that NAT carried no biological effects on the peripheral immune response. The purpose of our study was to assess the effects of NAT on the peripheral pro… 

Figures and Tables from this paper

References

SHOWING 1-10 OF 36 REFERENCES
Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action.
TLDR
IL-17F, sCD40L and IL-31 were the best biomarkers to assess the effectiveness of NAT, and NAT significantly decreased peripheral serum levels of some pro-inflammatory cytokines as a novel mechanism of action.
INTERFERON-β 1A, AN IMMUNOMODULATOR IN RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS. THE EFFECT ON PRO-INFLAMMATORY CYTOKINES
TLDR
The serum levels of the pro-inflammatory cytokines are higher in naïve recurrent-remissive multiple sclerosis patients compared to healthy controls, and treatment with Interferon-β significantly decreases the inflammatory profile.
Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid
TLDR
This is the first study to show that natalizumab treatment is associated with a global decline in cytokine and chemokine levels at a protein level, and this finding was most pronounced in CSF, in line with the reduced transmigration of cells into CNS, whereas reduction in plasma levels indicates other possible mechanisms of natalizer treatment.
Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment
TLDR
Increased lymphocytes and CD4+IL-17+ cells in the blood of RRMS patients receiving natalizumab corroborate the drug’s mechanism of action, that is, blocking transmigration to CNS.
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
TLDR
Natalizumab treatment increases the percentage of activated leukocytes producing proinflammatory cytokines in blood, presumably due to sequestration of activated cells in the peripheral circulation.
Clinical and Serological Biomarkers of Treatment's Response in Multiple Sclerosis Patients Treated Continuously with Interferonβ-1b for More than a Decade.
TLDR
After more than a decade of treatment, IFNβ-1b offers good results by reducing relapses and slowing disability progression, and IL-25 may exert a positive influence in male MS patients and should be considered for future studies.
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
TLDR
Assessing the Th17-cell/IL-17 axis might help to predict rebound MS activity after NAT withdrawal and became almost undetectable in blood samples of individuals who experienced relapses during the wash-out phase.
The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients
TLDR
Serum samples from MS patients were used to demonstrate if “cytokine signature” patterns can separate different patient groups better than using single cytokines, and showed that patients treated with natalizumab and interferons showed significantly reduced cytokine signature levels than drug naïve MS patients.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
TLDR
Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.
Natalizumab Therapy Modulates miR-155, miR-26a and Proinflammatory Cytokine Expression in MS Patients
TLDR
The expression of particular miRNAs modulates the pro-inflammatory cytokine expression and the humoral response against EBV and this expression is natalizumab regulated.
...
...